MICROFLUIDIC TECHNOLOGIES FOR POINT-OF-CARE DIAGNOSTIC SOLUTIONS ZetaGene Ltd. was funded by scientists from Lund University, Sweden in 2020. In the global response to fight the COVID-19 pandemic, it remains crucial to profile the true population epidemic, and provide knowledge on the nature of protection by acquired active immunity. ZetaGene aims to provide fast and precise serology assessment on SARS-CoV-2 antibody response in patients with COVID-19.